Follow Pfizer to never miss an important update.
Pfizer is partnering with Blackstone Life Sciences to fund the development of berobenatide, an experimental weight-loss drug. Blackstone will pay up to $1.5 billion in costs over the next two years for the drug, which is a monthly injection designed to help with chronic weight management.
This deal allows Pfizer to push forward in the competitive obesity market without spending its own cash upfront. By sharing the financial risk with an outside firm, Pfizer can maintain its aggressive research pace while protecting its own profits as it works to find a successor to its older, off-patent medicines.
Source: Business Wire
Pfizer has named Cecile Guegan as its permanent Chief Financial Officer and Executive Vice President, effective November 1, 2026. Ms. Guegan is a company veteran who joined Pfizer in 2009 and previously led finance for the Global Biopharmaceuticals business before stepping into the interim CFO role this past August.
Appointing an internal leader to the top finance spot suggests the company is focused on continuity as it manages a heavy stretch of spending on new drug development. While a CFO change is a major event, this was an orderly transition from an interim period, which should provide stability as the company works to offset revenue lost from older drugs losing their patent protections.
Source: 8-K filing
After Pfizer reported its November results, we updated our revenue and profit projections for the coming year. We have added the sales performance of the Prevnar vaccine franchise and the company's reliance on external partnerships to what we track. We also adjusted our expectations for research and development spending after those costs rose 18% over the last three months.
Pfizer earned $0.87 per share this quarter, which was about 18 percent higher than the $0.73 analysts expected. Sales reached $16.58 billion, also topping the $15.85 billion target. This growth was driven by a 32 percent jump in revenue from newly launched drugs and products acquired through recent deals, including its major push into cancer treatments.
Because of this momentum, management raised its full-year guidance for both revenue and profit. This is a positive sign for the company's plan to replace old revenue lost to expiring patents with newer, high-value medicines. The company also named Cecile Guegan, a twenty-year veteran of the firm, as its new Chief Financial Officer.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The FDA has expanded the use of Pfizer's drug Talzenna, allowing it to be used alongside another treatment for a specific type of metastatic prostate cancer. This new approval covers patients at an earlier stage of the disease than before, including those with a wider range of genetic mutations.
Moving a drug into earlier lines of treatment is a key way for pharmaceutical companies to reach more patients and increase sales. For Pfizer, this supports the goal of building a leading cancer portfolio to replace revenue lost as other major medicines lose their market exclusivity.
Source: Business Wire
Management consistently sets a bar they can clear, beating their own profit targets for eight straight quarters. This reliable execution shows they have a firm handle on the business even as it shifts away from pandemic-era products.
| Expectation | |
|---|---|
| EPS | $0.69 |
| Revenue | $17.22B |